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The inotropic and vasodilatory properties of 4,5-dihydro-6-phenylpyridazin-
-3(2H)-ones are well documented in literature (1–3). Pyridazinone derivatives like SK&F-
-93741, its nor-methyl derivative and levosimendan (Fig. 1) possess a substituted amino
group at para-position of 6-phenyl ring and have emerged as potent cardiotonic agents
with dual inotropic and vasodilatory properties in higher animals (4–6). These pyridazi-
none-based cardiotonics have shown good promise in the treatment of congestive heart
failure; however, species differences in inotropic response to these agents have been ob-
served (7). It is also evident from literature reports that the most dramatic alterations in
the potency of pyridazinone based cardiotonics result from varying para-substituents of
the phenyl ring attached to 4-position of pyridazinone nucleus. However, position 2 of
the pyridazinone ring remains relatively unexplored. Pyridazin-3(2H)-ones further drew
our attention because of their easy functionalization at various ring positions (1), which
makes them attractive synthetic building blocks for designing and development of novel
pyridazinone based cardiotonic agents.
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The present study describes the synthesis and pharma-
cological evaluation of 2-substituted-6-(4-acylaminophe-
nyl)-4,5-dihydropyridazin-3(2H)-ones as potent inodilating
agents. The synthesis of target compounds 2–4 and 7–11
was achieved by Friedel-Crafts acylation of appropriate
anilide derivative with succinic anhydride or methylsu-
ccinic anhydride and subsequent cyclization of interme-
diary keto acids with various hydrazine derivatives. The
newly synthesized pyridazinone derivatives were evalu-
ated for cardiotonic activity using isolated rat atria and
for vasorelaxant activity using descending thoracic aor-
tic rings of Wistar rats precontracted with phenylephrine
(10–6 mol L–1). 6-(4-Methanesulfonamidophenyl)-2-phen-
yl-4,5-dihydropyridazin-3(2H)-one (7) exhibited significant
inodilatory properties and showed vasorelaxant activity
in a nanomolar range (IC50 = 0.08 ± 0.01 mmol L–1).
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In the present study, several 2-substituted derivatives of 6-(4-acylaminophenyl)py-
ridazinones have been prepared and evaluated for their inotropic and vasodilatory pro-
perties to investigate the effects produced by incorporating substituents at 2-position of
the pyridazinone ring. Several sulphonamido pyridazinone derivatives were also syn-
thesized to compare their biological effects with their acetamido congeners. The synthe-
sis of target pyridazinones was achieved by the Friedel-Crafts acylation (8, 9) of anilides
with anhydrides of succinic acid and its 2-methyl derivative to afford g-keto acids, which
on subsequent cyclization using suitable hydrazine derivatives gave the target compounds
2–4 and 7–11.
EXPERIMENTAL
Melting points were determined on a Veego melting point apparatus (India) and are
uncorrected. Infrared spectra were recorded on a Perkin-Elmer 882 (UK) and a Perkin-
-Elmer spectrum RX 1, FT-IR spectrophotometer (Switzerland) using KBr pellets (nmax in
cm–1). Proton (1H) resonance spectra were recorded on a AC-300F, 300 MHz and Brucker
multinuclear FT NMR spectrometer, model AV-400, 400 MHz instrument (Brucker, Swit-
zerland) using tetramethylsilane as internal reference (chemical shifts in d, ppm). Plates
for TLC were prepared with silica gel G (Merck, India) and activated at 110 °C for 30
min. Ethyl acetate was used as solvent. Iodine was used to develop the spots. Elemental
analyses were carried out on a Perkin-Elmer-2400 model CHN analyzer (USA). All sol-
vents were distilled prior to use according to standard procedures. Anhydrous sodium
sulfate was used as drying agent.
Aluminium chloride, carbon disulfide, hydrazine hydrate, phenylhydrazine hydro-
chloride and succinic anhydride were obtained from S.D. Fine Chemicals (India), me-
thylsuccinic anhydride was obtained from Aldrich Chem. Co. (USA), 4-fluorophenylhy-
drazine from Lancaster (UK) and hydralazine hydrochloride was obtained ex gratis from
Prof. Alan Harvey (UK); 2-hydrazino-2-imidazoline hydrobromide was obtained ex gra-
tis from Organon labs (USA). Iodine, sodium bicarbonate, acetone, methanol and ether
were purchased from Qualigens Fine Chemicals (India).
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Fig. 1. Structural formulae of two pyridazinone based cardiotonic agents.
4-(4-Acetamidophenyl)-4-oxobutyric acid (1) was prepared by the reported proce-
dure (8).
Satisfactory analysis for C, H, N, within ± 0.4% of the theoretical values, was ob-
tained for all compounds.
Syntheses
6-(4-Acetamidophenyl)-2-substituted-4,5-dihydropyridazin-3(2H)-ones (2–4). – Requisite
hydrazine derivative (2.14 mmol) was added to a stirred and refluxing solution of 4-(4-
-acetamidophenyl)-4-oxobutyric acid (1) (2.13 mmol) in aldehyde free ethanol (40 mL).
The reaction mixture was refluxed for 8 h under continuous stirring. The reaction mix-
ture was concentrated to half the volume and left overnight in refrigerator for crystalli-
zation. The crystals obtained were collected on a filter, washed with cold ethanol, dried
and recrystallized from the appropriate solvent.
4-(4-Methanesulfonamidophenyl)-4-oxobutyric acids (5, 6). – A mixture of N-phenyl-me-
thanesulfonamide (5.0 g, 29.20 mmol) and succinic anhydride (2.8 g, 27.98 mmol)/me-
thyl succinic anhydride (2.8 g, 24.54 mmol) was added to a stirred solution of aluminum
chloride (18 g) in purified carbon disulphide (30 mL). The reaction mixture was stirred
manually under anhydrous conditions for 20 min and was allowed to stand for 48 h at
room temperature. Carbon disulphide was decanted and the mixture was decomposed
with crushed ice. The product obtained was filtered and washed thoroughly with distilled
water. The resulting solid was dissolved in 5% aqueous sodium bicarbonate solution
and filtered off the insoluble part. Acidification of the filtrate with concentrated hydro-
chloric acid gave a precipitate, which was collected on a filter, washed with water and
dried. The solid residue so obtained was recrystallized from methanol.
6-(4-Methanesulfonamidophenyl)-2-substituted-4,5-dihydropyridazin-3(2H)-ones (7–9). –
Requisite hydrazine derivative (1.90 mmol) was added to a stirred and refluxing solu-
tion of 4-(4-methanesulfonamidophenyl)-4-oxobutyric acid (5) (1.90 mmol) in aldehyde
free ethanol (40 mL). The reaction mixture was further refluxed under stirring for 7 h.
The resultant solution was concentrated to half the volume and left overnight in refrige-
rator for crystallization. The crystals obtained were collected on a filter, washed with
cold ethanol, dried and recrystallized from the appropriate solvent.
6-(4-Methanesulfonamidophenyl)-4,5-dihydropyridazin-3(2H)-ones (10, 11). – Hydrazine
hydrate (1.90 mmol) was added to a stirred and refluxing solution of 4-(4-methanesulfon-
amidophenyl)-4-oxobutyric acid (5)/4-(4-methanesulfonamidophenyl)-5-methyl-4-oxobu-
tyric acid (6) (1.90 mmol) in aldehyde free ethanol (40 mL). The reaction mixture was
further refluxed under stirring for 7 h. The resultant solution was concentrated to half
the volume and left overnight in refrigerator for crystallization. The crystals obtained
were collected on a filter, washed with cold ethanol, dried and recrystallized from ethanol.
Pharmacology
One hundred Wistar rats of either sex, weighing 300–400 g, were bred and housed
in the animal house of the University of Salamanca, Spain (P.A.E.-SA001) under stan-
dard laboratory conditions at 22 ± 3 °C, relative humidity 50–55% and 12 h light/dark
cycle. Drinking water and a nutritionally balanced synthetic pelleted diet were supplied
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ad libitum throughout the study period. Fifty animals were used for cardiotonic activity
experiments and fifty for vasodilatory activity. In all of these experiments, the provisions
regarding the protection of animals used for experimental purposes in current Spanish
legislation (Real Decreto 223/1988) and European Community (EEC 86/609) specifica-
tions were applied. All animal protocols were approved by the ethical committee of the
University of Salamanca.
Cardiotonic activity. – Animals were killed by cervical dislocation and their hearts
were rapidly removed (10). Right and left atria were dissected and mounted vertically in
10 mL organ baths containing Tyrode solution of the composition: NaCl (137 mmol L–1),
KCl (5.4 mmol L–1), CaCl2 (1.8 mmol L–1), MgCl2 (1.05 mmol L–1), NaHCO3 (11.6 mmol
L–1), NaH2PO4 (0.42 mmol L–1) and glucose (5.5 mmol L–1). The solution was bubbled
with O2/CO2 (95:5) and maintained at 34 °C. Under these conditions, the right atria beat
spontaneously, while the left atria were electrically driven at a basal rate of 3 Hz through
bipolar platinum electrodes with rectangular pulses (1 ms duration, twice threshold
strength) delivered from a multipurpose programmable stimulator (Cibertec CS 220,
Spain). The left atrium was maintained under constant electric stimulation and was
used to measure the effects of compounds on the contraction force, while the spontane-
ously beating right atrium was used to evaluate the effect on the contraction force as
well as on cardiac frequency. The assays were carried out by increasing cumulative con-
centrations of drugs from 10–9 to 10–3 mol L–1 at 20 min intervals as shown in Tables
II–IV. Rate and amplitude of contractions were measured isometrically by a force-dis-
placement transducer and recorded on a Grass Model 7B polygraph (Grass Instrument
Co., USA). Resting tension was adjusted to 1 g and a 30 min equilibration period was al-
lowed to elapse before control measurements were taken. After control values for each
parameter were obtained, incremental concentrations of each product were added every
20 min to the bath to obtain a complete concentration-response curve. The values for the
different parameters (rate and amplitude of contractions) obtained in the absence of each
product were used as controls and compared with those obtained after each increment
in product concentration.
The pyridazinone derivatives and reference compounds were dissolved in DMSO to
prepare a 10–2 mol L–1 stock solution, which was further diluted with Tyrode solution to
obtain final concentrations containing < 1% DMSO in the organ bath.
The results obtained from a minimum of 5 experiments were expressed as
mean ± SEM. Statistical analysis of the results was performed by unpaired Student’s
t-test.
Vasodilatory activity. – Vasodilatory activity of the compounds was studied using de-
scending thoracic aortic rings of Wistar rats precontracted with phenylephrine (10–6 mol
L–1) according to the reported method (11). Wistar rats of either sex, weighing 300–400 g,
were killed by a blow on the head. The descending thoracic aorta was rapidly dissected
and placed in a physiological saline solution (PSS) of the composition: NaCl (118 mmol
L–1), KCI (4.75 mmol L–1), NaHCO3 (25 mmol L–1), MgSO4 (1.2 mmol L–1), CaCI2 (1.8
mmol L–1), KH2PO4 (1.2 mmol L–1) and glucose (11 mmol L–1). After excess of fat and
connective tissue was removed, the aorta was cut into rings (4–5 mm in length), moun-
ted under the basal tension of 2 g in 5 mL organ baths containing physiological saline so-
lution and attached to force-displacement transducers to measure the isometric contrac-
tile force. The tissue bath was maintained at 37 °C and bubbled with an O2/CO2 (95:5)
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gas mixture. Each preparation was allowed to equilibrate for at least 90 min prior to ini-
tiation of experimental procedures and during that period the incubation media were
changed every 20 min.
After equilibration, aortic rings were contracted with a single concentration of phe-
nylephrine (l0–6 mol L–1). When the contractions were stable, compounds were added in
progressively increasing cumulative concentrations (10–8–10–5 mol L–1) at 30 min inter-
vals. Only one compound was tested in each ring. All the results were expressed as a
percentage of the maximal control phenylephrine-induced responses. All pyridazinone
derivatives and the reference compounds were initially dissolved in dimethyl sulfoxide
(DMSO) to prepare a 10–2 mol L–1 stock solution. Further solutions were made in physio-
logical saline solution. Hydralazine (10–8–10–5 mol L–1) and SK&F-93741 (10–8–10–5 mol L–1)
were used as reference compounds under the same experimental conditions.
RESULTS AND DISCUSSION
Friedel-Crafts acylation of acetanilide and N-phenylmethanesulfonamide using su-
ccinic anhydride or methylsuccinic anhydride in the presence of anhydrous aluminium
chloride (a Lewis acid) in purified carbon disulphide at room temperature afforded the
corresponding g-keto acids (1, 5) and b-methyl-g-keto acid 6 (8, 9). Subsequent cycliza-
tion reaction of g-keto acids 1 and 5 with various hydrazine derivatives such as phenyl-
hydrazine or 4-fluorophenylhydrazine hydrochlorides, or 2-hydrazino-2-imidazoline hy-
drobromide in aldehyde free ethanol afforded the pyridazinone derivatives 2–4 and 7–9,
respectively. The synthetic pathway is given in Schemes 1 and 2 and characterization
data for all new compounds are given in Table I. Methanesulfonamido substituted g-keto
acid 5 and its b-methyl analogue 6 were also treated separately with hydrazine hydrate
to afford respective 2-unsubstituted pyridazinones 10 and 11. Compound 11 was obtained
as a chiral molecule with a stereogenic center in the pyridazinone ring.
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Infrared spectrum of compounds 2–4 and 7–9 exhibited peaks in the region ~3300
cm–1 due to N–H stretching vibrations and characteristic amide C=O absorption bands
near 1690 and 1660 cm–1. In the NMR spectra of 2–4 and 7–9, pyridazinone C4 and C5
protons resonated as triplets at d 2.76 and 3.10 ppm, respectively. A downfield shift of C4
protons was observed in these 2-substituted derivatives in comparison to unsubstituted
ones (10 and 11) because of phenyl, 4-fluorophenyl and imidazolinyl substitution at ni-
trogen of the pyridazinone ring. Aromatic protons of the 6-phenyl ring were obtained as
doublets with protons ortho to amide at an upfield position in comparison to those pres-
ent at meta position for all the pyridazinone derivatives. 2-Unsubstituted –NH signal
was observed at d 10.41 ppm in the case of 10 and 11 while it was absent in the case of
2-substituted derivatives 2–4 and 7–9. The ratio of two enantiomers in 5-methyl deriva-
tive 11 could not be determined using proton NMR spectroscopy since all the protons
resonate at the same position in both isomers (12). The racemic mixture obtained was
used as such for further studies.
The effects of the compounds SK&F-93741, amrinone, isoprenaline, 2, 3, 7, 8, 10 and
11 on the amplitude of contraction on electrically driven rat isolated left atria and spon-
taneously beating rat isolated right atria are summarized in Tables II and III, respecti-
vely. The results are expressed as the percentage of control values obtained before incor-
poration of the compounds. Control value for the isometric contraction force in isolated
left atria was 260 ± 75 mg (n = 35). For the right atria, control values for the amplitude of
contraction and cardiac frequency were 279 ± 21 mg and 257 ± 14 beats min–1, respec-
tively (n = 35). Table IV presents the effects of the new compounds on the sinus rate in
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spontaneously beating rat isolated right atria. Imidazolinyl derivatives 4 and 9 could not
be assessed for cardiotonic activity because of limited solubility.
Of the newly synthesized 6-(4-acylaminophenyl)pyridazinone derivatives 2, 3, 7, 8,
10 and 11, tested for inotropic activity, 6-(4-methanesulfonamidophenyl)-2-phenyl-4,5-di-
hydropyridazin-3(2H)-one (7) produced a significant concentration dependent positive
inotropic effect. Introduction of the phenyl group at position 2 in the case of methane-
sulphonamido substituted pyridazinone derivative 7 resulted in potent cardiotonic ac-
tivity in comparison to 2-phenyl substituted acetamido congener 2. However, substitu-
tion of p-fluorophenyl moiety, as in 3 and 8, did not produce any change in cardiac res-
ponse in either series of compounds. Although the inotropic effect of compound 7 is ob-
served at higher concentrations compared to the standard drug isoprenaline, the increase
in contractility does not affect the cardiac frequency, whereas the inotropic effect of stan-
dard compound isoprenaline is associated with a great increase in sinus rate (Table IV).
The cardiotonic effect of 7 is also in sharp contrast to prototypical compounds SK&F-
-93741 and amrinone, whose inodilatory effects are believed to be mediated through pho-
sphodiesterase inhibition in higher animals (7, 13). Figure 2 shows the concentration-re-
sponse effect of 7 on the peak contractile force in spontaneously beating rat isolated left
atria, which is significant above 10–5 mol L–1. 2-Unsubstituted pyridazinones including
the newly synthesized compounds 10, 11 and representative compounds SK&F-93741 and
amrinone did not produce a substantial effect either on myocardial contractility or on
cardiac frequency, when tested in rats (Tables II–IV). Interestingly, negative inotropic ef-
fects indicating decreased myocardial contractility were observed for the inactive com-
pounds.
When tested for vasodilatory activity, many compounds produced a concentration
dependent inhibition of the contractile response of phenylephrine. The IC50 value means
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Table II. Effects of compounds on peak contractile force in rat isolated left atria electrically




10–9 10–8 10–7 10–6 10–5 3 ´ 10–5 10–4
2 0 0 0 –9.9 ± 1.6b –23.2 ± 2.9b –25.1 ± 3.9b –32.3 ± 1.7b
3 0 0 –3.6 ± 0.8b –10.2 ± 2.0b –15.6 ± 2.9b –24.4 ± 3.5b –32.1 ± 2.2
7 0 0 –1.1 ± 1.6 –2.0 ± 2.7 4.5 ± 2.9 33.3 ± 5.8b 67.8 ± 6.3b
8 0 0 9.2 ± 6.5 2.6 ± 7.3 –3.3 ± 8.8 –5.0 ± 10.4 –8.1 ± 10.4
10 0 0 –6.3 ± 3.6 16.0 ± 0.7b –21.6 ± 2.3b –27.8 ± 2.4b –34 ± 3.6b
11 0 0 –4.1 ± 3.2b –15.9 ± 2.7b –22.6 ± 4.0b –32.0 ± 3.8b –39.3 ± 3.8b
SK&F-93741 0 0 –1.0 ± 6.8 –3.5 ± 7.5 –0.6 ± 6.7 –5.7 ± 6.3 –5.0 ± 8.7
Isoprenaline 0.6 ± 0.6 2.8 ± 1.1b 10.8 ± 3.2b 63.0 ± 15.7b 85.8 ± 18.8b – –
Amrinone 0 0 0 –1.6 ± 3 –6.7 ± 2.9 –12.8 ± 3.6 –23.5 ± 6.7b
a Mean ± SEM, n = 5.
b Significantly different from control: p < 0.05.
All compounds were initially dissolved in DMSO to prepare a 10–2 mol L–1 stock solution, which was further
diluted with Tyrode solution to obtain final concentrations containing < 1% DMSO in the organ bath.
the concentration producing 50% relaxation of maximal control phenylephrine-induced
responses of various pyridazinone derivatives 2–4, 7, 8, 10 and 11 (Table V). Methanesul-
phonamide substituted pyridazinone derivatives 7 and 8 with phenyl and p-fluorophenyl
groups at position 2 displayed potent vasodilatory activity compared to their acetamide-
-substituted counterparts 2 and 3, which did not produce 50% relaxation up to 10–5 mol
L–1. In the acetamide series, only imidazolinyl derivative 6 displayed intermediate po-
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10–9 10–8 10–7 10–6 10–5 3 ´ 10–5 10–4
2 0 0 0 0 –6.3 ± 3.3b 4.3 ± 13.7b 6.3 ± 13.5b
3 0 0 0 0 –3.0 ± 1.6b –9.0 ± 1.9b –18.4 ± 1.7b
7 0 0 7.2 ± 4.7 1.7 ± 2.6 –9.3 ± 4.7 43.3 ± 9.5b 1 12 ± 16.7b
8 0 0 0.04 ± 1.4 –1.7 ± 3.2 –3.9 ± 2.8 –5.8 ± 3.7 –5.8 ± 8.3
10 0 0 0 –4.8 ± 2.8b –8.4 ± 5.0b –9.9 ± 4.6b –8.4 ± 4.9b
11 0 0 –5.0 ± 1.5b –12.2 ± 1.2b –19.6 ± 0.8b –25.6 ± 1.8b –27.3 ± 1.4b
SK&F-93741 0 –1.0 ± 2.8 –4.7 ± 2.4 –3.4 ± 3.5 –4.3 ± 5.2 –7.3 ± 6.7
Isoprenaline 43.9 ± 9.3b 101.4 ± 17b 106 ± 2.1b 67.1 ± 17.5b 47.9 ± 16.2b – –
Amrinone 0 0 0 3.7 ± 1.9b 6.1 ± 2.8b 3.2 ± 2.6b 24.8 ± 6.2b
a Mean ± SEM, n = 5.
b Significantly different from control: p < 0.05.
All compounds were initially dissolved in DMSO to prepare a 10–2 mol L–1 stock solution, which was further
diluted with Tyrode solution to obtain final concentrations containing < 1% DMSO in the organ bath.




10–9 10–8 10–7 10–6 10–5 3 ´ 10–5 10–4
2 0 0 4.5 ± 3.6b –0.7 ± 1.7 –3.8 ± 3.0b –6.9 ± 2.7b –9.3 ± 2.7b
3 0 0 –1.7 ± 1.8 –2.6 ± 2.8 0.3 ± 4.1 –2.5 ± 1.4b –0.3 ± 2.6b
7 0 0 –0.2 ± 1.5 –3.9 ± 2.7 –2.9 ± 2.0 –2.1 ± 3.1 0.2 ± 3.5
8 0 0 –0.05 ± 1.7 –3.2 ± 1.7 –3.5 ± 1.5 –2.6 ± 2.3 1.2 ± 2.1
10 0 0 –12.3 ± 3.0b –16.0 ± 3.4b –17.5 ± 3.1b –19.6 ± 3.0b –22.7 ± 0.8b
11 0 0 0 0 –0.6 ± 0.3b –4.8 ± 1.7b –12.7 ± 0.4b
SK&F-93741 0 0 0.7 ± 0.7 0.7 ± 1.9 0.7 ± 2.6 2.9 ± 3.2 6.6 ± 3.6
Isoprenaline 16.6 ± 3.3b 44.9 ± 7.0b 58.3 ± 7.5b 62.1 ± 6.4b 62.6 ± 6.2b – –
Amrinone 0 0 0 5.1 ± 1.3b 6.9 ± 1.9b 10.4 ± 2.6b 32.1 ± 5.0b
a Mean ± SEM, n = 5.
b Significantly different from control: p < 0.05.
All compounds were initially dissolved in DMSO to prepare a 10–2 mol L–1 stock solution, which was fur-
ther diluted with Tyrode solution to obtain final concentrations containing < 1% DMSO in the organ bath.
tency (IC50 = 2.51 mmol L–1). The most active compound 7 (IC50 = 0.079 mmol L–1) pro-
duced vasorelaxation better than the reference compound hydralazine and prototypical
compound SK&F-93741. Imidazolinyl derivative 9 could not be screened for vasodila-
tory activity because of poor solubility. 2-Unsubstituted derivative 10 possessing metha-
nesulphonamido functionality and compound SK&F-93741 bearing an acetamido group
were equipotent in producing vasorelaxation (Table V). It can be said that substitution of
methanesulphonamido group at the para position of 6-phenylpyridazinones results in
potent vasodilatory activity, which is further improved by 2-substitution.
Although earlier research work indicated that an acidic proton adjacent to dipolar
moiety in the pyridazinone ring system is essential for optimum inodilating activity
through phosphodiesterase inhibition, 2-substitution resulted in good inodilating pro-
perties in this study. Further investigations are required to elucidate the exact mecha-
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Table V. IC50 values of pyridazinone derivatives to inhibit
contractions induced by phenylephrinea,b
Compd. No. IC50 (mmol L–1)
2c –
3c –
4 2.51 ± 0.2
7 0.079 ± 0.01
8 3.98 ± 0.3
10 0.199 ± 0.2
11c –
Hydralazine 0.316 ± 0.1
SK&F-93741 0.199 ± 0.2
a 10–6 mol L–1 phenylephrine
b Mean ± SEM, n = 5–8.
c Compounds which did not produce 50% relaxation up to 10–5 mol L–1.
All compounds were initially dissolved in DMSO to prepare a 10–2 mol L–1 stock solution, which was further
diluted with physiological saline solution to obtain final concentrations containing < 1% DMSO in the organ bath.




























Fig. 2. Concentration-response effects of
compound 7 on peak contractile force
in Wistar rat isolated left atria. Each
value represents the mean of at least
five experiments; vertical bars represent
the SEM. * Significantly different from
control: p < 0.05.
nism of action of these pyridazinones, which is probably mediated either by combined
calcium sensitization and phosphodiesterase 3 inhibition or release of cycloxygenase
products or opening of K+-channels. However, the pharmacological effects observed
provide information about the therapeutic interest of pyridazinone derivatives in heart
failure and hypertension.
CONCLUSIONS
In the current study, newly synthesized 2-substituted pyridazinones bearing a me-
thanesulphonamido group at para position of the 6-phenyl ring exhibited a significant
concentration dependent positive inotropic effect and potent vasodilatory activity in rats.
This dual inhibition could be of interest for the treatment of congestive heart failure to
reduce preload and afterload on the heart.
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S A @ E T A K
Sinteza i farmakolo{ko vrednovanje 2-supstituiranih-6-fenil-
-4,5-dihidropiridazin-3(2H)-ona kao sna`nih sr~anih stimulatora
DINESH KUMAR, ROSALIA CARRON, CARMEN DE LA CALLE, DHARAM PAUL JINDAL i RANJU BANSAL
U radu je opisana sinteza i framakolo{ko vrednovanje 2-supstituiranih-6-(4-acilami-
nofenil)-4,5-dihidropiridazin-3(2H)-ona kao sna`nih sr~anih stimulatora. Spojevi 2–4 i
7–11 sintetizirani su Friedel-Craftsovim acilaranjem odgovaraju}eg anilida s anhidridom
jantarne ili anhidridom metiljantarne kiseline te ciklizacijom intermedijarnih keto kise-
lina s razli~itim derivatima hidrazina. Kardiotoni~no djelovanje novosintetiziranih deri-
vata piridazinona ispitano je na izoliranim atrijima {takora, a vazodilatiraju}e djelovanje
na silaznim torakalnim prstenima aorte prethodno kontrahiranim fenilefrinom (10–6 mol
L–1). 6-(4-Metansulfonamidofenil)-2-fenil-4,5-dihidropiridazin-3(2H)-on (7) pokazao je
zna~ajno stimulativno i vazodilatiraju}e djelovanje u nanomolarnim koncentracijama
(IC50 = 0,08 ± 0,01 mmol L–1).
Klju~ne rije~i: piridazinoni, anilidi, derivati hidrazina, kardiotoni~no djelovanje, vazodilatacijsko
djelovanje
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